Clinical Trials Logo

Clinical Trial Summary

This study will reach out to patients who have undergone diagnostic testing for the following respiratory illnesses from January 1st, 2018 to July 9th, 2023: COVID-19, Influenza, Rhinovirus, and Respiratory Syncytial Virus. This study aims to develop a forecasting model to predict infection onset prior to symptom onset using wearable device data and known symptom onset and test dates.


Clinical Trial Description

DUHS patients who have diagnostic testing for Influenza, COVID-19, Respiratory syncytial virus, and Rhinovirus testing within the past 5 years will be initially screened for an email address. Participants will learn about this study via email with a link to complete the survey. A Study ID will be generated for all individuals with an email. Participants will be asked to complete an e-consent via a REDCap survey. If participants have questions, they are provided with study contact information via e-mail. Participants will complete the survey which will have questions on prior symptoms and device ownership (anticipated time to complete: 5 minutes). If the participant owns one of the following wearable devices (Fitbit, Garmin, or Apple Watch), they will be sent to a redirect URL to login into their device account (for Fitbit or Garmin) or be provided with instructions to export their Healthkit data and dump their data into a unique Strongbox link (for Apple Watch). If participants choose to contribute their wearable device data to the study and the data obtained pass through data quality thresholds, they will receive compensation. There is no compensation for survey completion. The investigators will ask participants if they wish to be re-contacted for future studies related to this project. The investigators will collect endpoint data values from the wearable. These data will be used to estimate daily activity amounts and intensity (i.e., exercise and walking), standing, sleep amounts, sleep quality, heart rate variability, SpO2, respiratory rate, and heart rate. All of the wearable device data will be identified using a Study ID. The investigators will use statistical and machine learning models to develop personalized "baseline" models of health and detect anomalies that can help in identifying COVID-19 infection. The investigators will validate and test the sensitivity and specificity of our mode for detecting respiratory infection vs. no infection against symptom surveys and diagnostic testing as ground truth. The model testing and validation will be done separately for each brand of device and will be further modified according to the type of respiratory infection. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04623047
Study type Observational
Source Duke University
Contact
Status Completed
Phase
Start date June 28, 2023
Completion date June 4, 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03698084 - RESCEU: Defining the Burden of RSV Disease
Completed NCT04090658 - A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults Phase 1
Completed NCT04231968 - A Study of AK0529 in Chinese Infants Hospitalized With RSV Phase 3
Completed NCT03227029 - Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age Phase 1
Completed NCT02873286 - RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults Phase 2
Completed NCT02984280 - Specific Respiratory Infections as Triggers of Acute Medical Events N/A
Withdrawn NCT02864628 - RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults. Phase 1
Terminated NCT02948127 - Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age Phase 1
Completed NCT02237209 - Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children Phase 1
Completed NCT02040831 - Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children Phase 1
Completed NCT02247726 - RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women. Phase 2
Completed NCT01915394 - Respiratory Syncytial Virus Infection in Neonatal Intensive Care Units Throughout Turkey: Prospective Multicenter Study (TurkNICU-RSV Trial) N/A
Completed NCT01355016 - A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers Phase 1
Completed NCT00232635 - A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT Phase 2
Completed NCT01155193 - Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany
Not yet recruiting NCT06083623 - A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants Phase 2/Phase 3
Terminated NCT02890381 - Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age Phase 1
Active, not recruiting NCT03422237 - Evaluating the Infectivity, Safety, and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants and Children 6 to 24 Months of Age Phase 1
Completed NCT03674177 - A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women Phase 1
Completed NCT01968083 - Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children Phase 1